ClinicalTrials.gov 临床试验·· 19 天前AI 评分18
APT-001(Spinosad 1.8%)外用治疗睑缘炎的2期疗效与安全性研究
A Phase 2 Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis
AI 导读
一项2期研究将评估新型外用制剂APT-001(Spinosad 1.8%)对比安慰剂治疗睑缘炎患者的临床疗效,并确认其安全性和总体耐受性。
来源:ClinicalTrials.gov 临床试验 · clinicaltrials.gov